Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.

Alamo (ALG)

Consensus Price Target: $219.75 (8.2% implied return)

Expanding its markets through acquisitions since its founding, Alamo (NSYE:ALG) designs, manufactures, and services vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use.

Why Are We Wary of ALG?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 1.3% annually over the last two years
2. High input costs result in an inferior gross margin of 25.5% that must be offset through higher volumes
3. Earnings per share have dipped by 5.7% annually over the past two years, which is concerning because stock prices follow EPS over the long term

Alamo’s stock price of $203.03 implies a valuation ratio of 18.6x forward P/E. Dive into our free research report to see why there are better opportunities than ALG.

Valmont (VMI)

Consensus Price Target: $490.25 (7.8% implied return)

Credited with an invention in the 1950s that improved crop yields, Valmont (NYSE: VMI) provides engineered products and infrastructure services for the agricultural industry.

Why Do We Think Twice About VMI?

1. Flat sales over the last two years suggest it must find different ways to grow during this cycle
2. Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 4.2%
3. Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 28.5%

Valmont is trading at $454.61 per share, or 20.1x forward P/E. If you’re considering VMI for your portfolio, see our FREE research report to learn more.

Exact Sciences (EXAS)

Consensus Price Target: $105.81 (2.5% implied return)

With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ: EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test.

Why Does EXAS Worry Us?

1. Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
2. Push for growth has led to negative returns on capital, signaling value destruction, and its shrinking returns suggest its past profit sources are losing steam
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $103.25 per share, Exact Sciences trades at 90.6x forward P/E. Dive into our free research report to see why there are better opportunities than EXAS.

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.